⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

January 1, 2020SHILAP Revista de lepidopterologíaOpen Access

Blood‐based biomarkers for Alzheimer's pathology and the diagnostic process for a disease‐modifying treatment: Projecting the impact on the cost and wait times

View Full Paper

Ask AI

Bookmark

Share

Abstract

The combination BBBM with MMSE is projected to increase the efficiency and value of the triage process for DMT eligibility.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mattke et al. (2020) studied this question.

synapsesocial.com/papers/69daa43b84371aa676a3d944 https://doi.org/10.1002/dad2.12081

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosisCohort Study · 2017 · 626 citations
2The Transition From Home to Nursing Home Mortality Among People With DementiaOriginal Research · 2000 · 120 citations
3Missed and Delayed Diagnosis of Dementia in Primary CareSystematic Review · 2009 · 1,002 citations
4Rate of progression of mild cognitive impairment to dementia – meta‐analysis of 41 robust inception cohort studiesCohort Study · 2009 · 1,684 citations
5Measuring Alzheimer’s disease progression with transition probabilitiesRegistry Study · 2001 · 115 citations